Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Natalizumab in Crohn's Disease Patients on Remicade
NCT00055536Phase 2Completed
- Sponsor
- Biogen
- Start
- Apr 2002
- Primary completion
- Jul 2003
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of natalizumab in Crohn's disease, sponsored by Biogen. Started Apr 2002; status: completed.
02
Drugs
natalizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT00055536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00055536.